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ARTICLE
Febuxostat, But Not Allopurinol, Markedly Raises the 
Plasma Concentrations of the Breast Cancer Resistance 
Protein Substrate Rosuvastatin
Minna Lehtisalo1,2, Jenni E. Keskitalo1,2, Aleksi Tornio1,2, Outi Lapatto-Reiniluoto1,2, Feng Deng1,2, Taina Jaatinen3,  
Jenni Viinamäki1,2, Mikko Neuvonen1,2, Janne T. Backman1,2 and Mikko Niemi1,2,*
Xanthine oxidase inhibitors febuxostat and allopurinol are commonly used in the treatment of gout. Febuxostat inhibits the 
breast cancer resistance protein (BCRP) in vitro. Rosuvastatin is a BCRP substrate and genetic variability in BCRP mark-
edly affects rosuvastatin pharmacokinetics. In this study, we investigated possible effects of febuxostat and allopurinol on 
rosuvastatin pharmacokinetics. In a randomized crossover study with 3 phases, 10 healthy volunteers ingested once daily 
placebo for 7 days, 300 mg allopurinol for 7 days, or placebo for 3 days, followed by 120 mg febuxostat for 4 days, and a 
single 10 mg dose of rosuvastatin on day 6. Febuxostat increased the peak plasma concentration and area under the plasma 
concentration-time curve of rosuvastatin 2.1-fold (90% confidence interval 1.8–2.6; P  =  5  ×  10−5) and 1.9-fold (1.5–2.5; 
P = 0.001), but had no effect on rosuvastatin half-life or renal clearance. Allopurinol, on the other hand, did not affect rosuv-
astatin pharmacokinetics. In vitro, febuxostat inhibited the ATP-dependent uptake of rosuvastatin into BCRP-overexpressing 
membrane vesicles with a half-maximal inhibitory concentration of 0.35 µM, whereas allopurinol showed no inhibition with 
concentrations up to 200 µM. Taken together, the results suggest that febuxostat increases rosuvastatin exposure by inhib-
iting its BCRP-mediated efflux in the small intestine. Febuxostat may, therefore, serve as a useful index inhibitor of BCRP 
in drug-drug interaction studies in humans. Moreover, concomitant use of febuxostat may increase the exposure to BCRP 
substrate drugs and, thus, the risk of dose-dependent adverse effects.
Gout is an increasingly common condition, and the most 
common form of inflammatory arthritis in developed coun-
tries. The main cause of gout is chronic hyperuricemia. 
Elevated serum uric acid concentration leads to accumu-
lation of monosodium urate in joints, where urate crystals 
cause an extremely painful inflammatory arthritis and re-
current gout flares. Risk factors for gout include obesity, 
renal failure, genetic variability, diet, medications, such as 
diuretics, and excessive consumption of alcohol.1–4 The 
increasing prevalence rates of gout worldwide are concor-
dant with the role of lifestyle in its development.
Allopurinol is the first-line treatment of chronic hyper-
uricemia and gout. It is used as a long-term medication 
to prevent attacks of gout and avoid permanent damage 
to the joints. Being a nonselective inhibitor of the xanthine 
oxidase enzyme, allopurinol prevents biotransformation of 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Rosuvastatin is a known substrate of breast cancer re-
sistance protein (BCRP). Recent in vitro findings indicate 
that the urate-lowering drug febuxostat inhibits BCRP at 
clinically relevant concentrations. Febuxostat also mark-
edly increased the exposure to the BCRP substrate 
 sulfasalazine in mice. Allopurinol is not known to inhibit 
BCRP in vitro.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ This study investigated possible effects of febuxostat 
and allopurinol on rosuvastatin pharmacokinetics in healthy 
volunteers.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE?
✔ Febuxostat almost doubles the exposure to rosuvastatin in 
healthy volunteers, whereas allopurinol has no effect on the 
rosuvastatin pharmacokinetics. The mechanism underlying 
the febuxostat-rosuvastatin interaction is likely inhibition of the 
BCRP-mediated efflux of rosuvastatin in the small intestine.
HOW THIS MIGHT CHANGE CLINICAL PHARMA COL- 
OGY OR TRANSLATIONAL SCIENCE?
✔  Potential BCRP-mediated interactions should be taken 
into consideration when planning urate-lowering therapy 
for patients with multiple medications. Febuxostat may be 
a useful probe inhibitor for BCRP in humans.
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hypoxanthine to xanthine and xanthine further to uric acid. 
Many patients on allopurinol, however, fail to achieve the 
target serum uric acid levels.5 In addition, some patients 
on allopurinol experience cutaneous adverse effects, rang-
ing from mild rash to severe, but rare, cutaneous adverse 
reactions associated with the HLA-B*58:01-allele,6,7 neces-
sitating discontinuation of allopurinol treatment.
Febuxostat is a newer xanthine oxidase inhibitor, which 
can be used as an alternative to allopurinol in the treat-
ment of gout. Febuxostat was recently found to strongly 
inhibit the breast cancer resistance protein (BCRP; en-
coded by ABCG2) mediated transport of urate in vitro 
and to markedly increase the exposure to the BCRP sub-
strate sulfasalazine in mice.8 BCRP is an efflux transporter 
expressed on the apical membrane of epithelial cells in 
the gastrointestinal wall, liver canalicular membranes, 
blood-brain barrier, placental syncytiotrophoblasts, testis, 
and the apical membrane of proximal tubular cells in the 
kidneys.9 BCRP can limit the oral bioavailability of its sub-
strates and enhance their excretion into the bile and urine. 
The most convincing evidence for a role of BCRP in drug 
pharmacokinetics comes from pharmacogenetic studies 
demonstrating increased exposure to BCRP substrate 
drugs in carriers of reduced function ABCG2 variants.10 For 
example, the area under the plasma concentration-time 
curve (AUC) of the cholesterol-lowering drug rosuvasta-
tin is increased 2.4-fold in individuals homozygous for 
the ABCG2 c.421C>A (p.Gln141Lys, rs2231142) reduced 
function single nucleotide variation (SNV), as compared 
with noncarriers.11
Patients with gout often receive medications for multiple 
comorbid conditions. Therefore, we found it important to in-
vestigate the potential pharmacokinetic interactions of the 
xanthine oxidase inhibitors febuxostat and allopurinol with 
the BCRP substrate rosuvastatin. To this end, we carried 
out a randomized, placebo-controlled, crossover study to 
investigate possible effects of febuxostat and allopurinol on 
rosuvastatin pharmacokinetics in healthy subjects.
METHODS
Subjects and study design
Following a written informed consent, 10 healthy volunteers 
participated in the study (Table 1). The participants’ health 
was confirmed by medical history, physical examination, 
and routine laboratory tests before entering the study. The 
participants were genotyped for the HLA-B*58:01 allele 
and carriers of the allele were excluded from the study. 
Genotyping for the HLA-B*58:01 allele was carried out in 
the Finnish Red Cross Blood Service (Helsinki, Finland) 
using the Luminex bead array technology (One Lambda, 
Los Angeles, CA) together with sequence-specific prim-
ers (Olerup, Stockholm, Sweden). None of the participants 
used any continuous medication, including hormonal con-
traception, and all were nonsmokers.
The study protocol was approved by the Coordinating 
Ethics Committee of the Helsinki and Uusimaa Hospital 
District (record number HUS/2942/2017) and the Finnish 
Medicines Agency Fimea (EudraCT number 2016-002297-
13). In a randomized, crossover study with three phases, 
the volunteers ingested as pretreatment either placebo 
(placebo tablets; University Pharmacy, Helsinki, Finland) 
once daily for 7 days; or 300 mg allopurinol (Apurin Sandoz; 
Lek Pharmaceuticals d.d., Ljubljana, Slovenia) once daily 
for 7  days; or placebo for 3  days (days 1–3) followed by 
120  mg febuxostat (Adenuric, Menarini—Von Heyden 
GmbH, Dresden, Germany) once daily for 4  days (days 
4–7; Figure 1). The participants were randomized to all six 
possible pretreatment sequences. A single 10 mg dose of 
rosuvastatin (Crestor; AstraZeneca UK Ltd., Cheshire, UK) 
was administered at 9 am on day 6, 1 hour after the intake 
of placebo, allopurinol, or febuxostat. Between the days of 
rosuvastatin administration, there was a washout period of 
3 weeks (2 weeks washout between the last day of pretreat-
ment of the previous phase and the first day of pretreatment 
in the next phase).
The volunteers fasted overnight before the days of rosu-
vastatin administration. A standard warm meal was served 
4 hours, and light meals 7 and 10 hours after the ingestion 
of rosuvastatin. The participants were not allowed to use 
any grapefruit products during the study. No other drugs 
were allowed from 1 week before to 1 week after the days of 
rosuvastatin administration. Use of alcohol was prohibited 
during the pretreatment and the days of rosuvastatin admin-
istration in each phase.
On the days of rosuvastatin administration, timed 4 mL 
EDTA venous blood samples were drawn before the admin-
istration of pretreatment, and 5 minutes prior to and 0.5, 1, 
1.5, 2, 3, 4, 5, 6, 7, 8, 10, 23, and 47 hours after rosuvasta-
tin ingestion for the determination of drug concentrations. 
The sample tubes were placed on ice immediately after 
sampling, and plasma was separated within 30  minutes. 
Urine was collected up to 10 hours after rosuvastatin inges-
tion. Plasma and urine aliquots were stored at –70°C until 
analysis.
Analysis of drug concentrations in plasma and urine 
samples
Rosuvastatin, allopurinol, febuxostat, and the corre-
sponding stable isotope-labeled internal standards were 




Age, years 26 ± 4 (21–35)
Weight, kg 76 ± 14 (58–98)









Data are given as mean ± SD (range), except for sex and the ABCG2 and 
SLCO1B1 genotypes, which are given as number of participants.
BMI, body mass index.
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purchased from Toronto Research Chemicals (North York, 
Ontario, Canada). Oxypurinol and its isotope analog were 
purchased from Santa Cruz Biotechnology (Dallas, TX). 
Other reagents and organic solvents were commercially 
available analytical grade. Deionized water was obtained 
from an in-house PRIMA water purification system (ELGA 
LabWater, High Wycombe, UK).
For the determination of rosuvastatin, plasma samples 
(150  µL) were mixed with acetonitrile (450  µL) containing 
the internal standard, and the mixture was filtered using 
a Phree Phospholipid Removal 96-well extraction plate 
(Phenomenex, Torrance, CA). The supernatants were 
then evaporated using a centrifugal evaporator (GeneVac, 
Thermo Fisher Scientific, Waltham, MA) and reconstituted in 
100 µL of 0.1% formic acid:acetonitrile (80:20, v:v).
The sample pretreatment for urine samples was per-
formed with Strata-X solid-phase extraction cartridges 
(10 mg/cartridge; Phenomenex), which were preconditioned 
with methanol and water according to the manufacturer’s in-
structions. Internal standard and 100 µL of phosphate buffer 
(0.1 M, pH 7.4) were added to 100 µL urine sample, and the 
sample was drawn through the cartridge followed by 200 µL 
of 20% methanol. Rosuvastatin was eluted with 2 × 100 µL 
of 1% formic acid in acetonitrile and reconstituted in 0.1% 
formic acid:acetonitrile (80:20, v:v).
Rosuvastatin concentrations were determined by using a 
Shimadzu Nexera liquid chromatography system (Shimadzu, 
Kyoto, Japan) coupled to an API 3000 tandem mass spectrome-
ter (AB Sciex, Toronto, Ontario, Canada). The chromatographic 
separation was performed with a Kinetex C18 column (2.6 µm 
particle size, 2.1 mm × 50 mm internal diameter; Phenomenex) 
equipped with a Kinetex C18 pre-column. The mobile phase 
consisted of 0.1% formic acid in water (A) and acetonitrile (B), 
and the mobile phase gradient was from 15% B to 95% B. 
The mobile phase flow rate was set at 300 µL/minute and the 
injection volume was 10 µL. The mass spectrometric detection 
was performed using electro-spray ionization in positive mul-
tiple reaction monitoring (MRM) mode, and the targeted ion 
transition was a mass-to-charge ratio (m/z) 482 to m/z 258. 
The lower and upper limits of quantification in plasma were 
0.1 ng/mL and 50 ng/mL. The intra-day coefficient of variation 
of the method was 3.2% (n = 5) and day-to-day coefficient of 
variation was 6.9% (n = 30) at relevant concentrations.
For the determination of allopurinol and febuxostat, the 
plasma samples were pretreated using simple protein pre-
cipitation with acetonitrile containing 1% formic acid and 
isotope-labeled internal standards. The supernatants were 
then diluted with water prior to liquid chromatography mass 
spectrometry analysis. All measurements were carried out 
using a Nexera X2 UHPLC system (Shimadzu, Kyoto, Japan) 
coupled to a 5500 Qtrap or a 6500 Qtrap mass spectrom-
eter interfaced with an electrospray ion source (AB Sciex, 
Toronto, Ontario, Canada).
Plasma allopurinol and oxypurinol were separated on a 
Luna Omega Polar C18 column using a mobile phase con-
sisting of 0.2% acetic acid (A) and acetonitrile (B). The mobile 
phase gradient was a linear ramp of B from 4% to 23% over 
2 minutes, followed by a washing step (90% B) and an equil-
ibration back to the starting composition. The flow rate and 
the column temperature were maintained at 200 µL/minute 
and 30°C. The mass spectrometer (5500 Qtrap) was oper-
ated in a negative polarity mode and the targeted MRM m/z 
ion transitions were 135 to 92 for allopurinol and 151 to 42 
for oxypurinol.
Figure 1 Study design. In a randomized crossover study, 10 healthy individuals ingested as pretreatment either placebo, 120 mg 
febuxostat, or 300 mg allopurinol once daily at 8 am. On day 6 of each phase, the participants ingested 10 mg of rosuvastatin at 9 
am. There was a washout period of 2 weeks between the last day of pretreatment and the start of the pretreatment in the next phase.
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The chromatographic separation of plasma febuxostat 
was performed on a Kinetex C18 column (2.6 µm particle 
size, 2.1  ×  100  mm internal diameter; Phenomenex). The 
mobile phase gradient was a mixture of 0.05% formic acid 
(A) and acetonitrile (B) as follows: 0.5 minutes at 25% B on 
hold, a linear ramp from 25% B to 95% B over 2.5 minutes, 
and 2 minutes at 95% B on hold followed by equilibration 
back to 25% B. The mobile phase was delivered at 250 µL/
minute and the oven temperature was set at 30°C. The mass 
spectrometer (6500 Qtrap) was operated in positive MRM 
mode using the characteristic m/z transition of 317 to 261 
for febuxostat. The lower limits of quantification were 5.0 ng/
mL, 100  ng/mL, and 10  ng/mL for allopurinol, oxypurinol, 
and febuxostat, respectively. The day-to-day coefficients of 
variation were below 15% for all analytes in relevant drug 
concentrations.
Pharmacokinetics
The pharmacokinetic variables (peak plasma concentra-
tion (Cmax); time to Cmax, time of peak plasma concentration 
(Tmax); AUC from zero to infinity (AUC0–∞) for rosuvastatin 
and dose-interval AUC from zero to 24 hours (AUC0–24) for 
allopurinol and febuxostat; elimination half-life (t½); amount 
excreted into urine; and renal clearance (Clrenal)) of ro-
suvastatin, allopurinol, and febuxostat were calculated 
by standard noncompartmental methods using Phoenix 
WinNonlin, version 8.1 (Certara, Princeton, NJ).
Genotyping
Genomic DNA was extracted from buffy coats using the 
Maxwell 16 LEV Blood DNA Kit on a Maxwell 16 Research 
automated nucleic acid extraction system (Promega, 
Madison, WI). The samples were genotyped for the 
ABCG2 c.421C>A (rs2231142) and SLCO1B1 c.521T>C 
(rs4149056) SNVs using TaqMan genotyping assays with 
OpenArray technology on a QuantStudio 12K Flex Real-
Time polymerase chain reaction system (Life Technologies, 
Carlsbad, CA).
Statistical analysis
The number of subjects was estimated to be sufficient 
to detect a potentially clinically meaningful effect size of 
30% difference in the AUC0–∞ of rosuvastatin among the 
3 phases, with a power of 80% (α-level 5%). The data were 
analyzed using the IBM SPSS Statistics for Windows, ver-
sion 25 (Armonk, NY). Before analysis, the pharmacokinetic 
parameters, apart from Tmax, were logarithmically trans-
formed. Statistical comparisons between the phases were 
made using repeated-measures analysis of variance with 
treatment phase as a within-subjects factor. The results are 
given as geometric means with geometric coefficients of 
variation and geometric mean ratios with 90% confidence 
intervals (CIs), except for Tmax, which is given as median 
with range. Any P values < 0.05 were considered statisti-
cally significant.
In vitro transport assays with BCRP-expressing 
plasma membrane vesicles
The vesicular transport assays were carried out with 
membrane vesicles produced from BCRP-overexpressing 
human embryonic kidney (HEK293) cells (PharmTox; 
Radboud UMC, Nijmegen, The Netherlands). The assays 
were performed essentially as described previously,12 
with rosuvastatin as a probe substrate at a final con-
centration of 5 µM. In short, membrane vesicles (7.5 µg) 
were incubated in transport assay buffer (PharmTox; 
Radboud UMC) supplemented with 10  mM MgCl2, to 
which various concentrations of febuxostat or allopuri-
nol, or vehicle was added. The plate was preincubated at 
37°C for 10 minutes. After the preincubation, the trans-
port was started by adding prewarmed Mg-ATP solution 
(final concentration 4 mM) or distilled water to the wells. 
The samples were incubated at 37°C for 5 minutes, after 
which transport was terminated with 200  µL ice-cold 
stop buffer (PharmTox; Radboud UMC), and the sam-
ples were immediately transferred on a MultiScreenHTS 
FB Filter Plate 1.0 μm/0.65 μm (Merck KGaA, Darmstadt, 
Germany). The vesicles were washed twice with 200  μl 
stop buffer and twice with ice-cold washing buffer 
(40  mM MOPS-Tris pH 7.0 and 70  mM KCl), and dried. 
Rosuvastatin was subsequently eluted from the wells 
with 50% methanol containing stable isotope-labeled ro-
suvastatin as internal standard and quantified with the 
5500 Qtrap mass spectrometer using the method pa-
rameters described above for the plasma samples. All 
assays were performed in triplicates on 96-well plates. 
Ko143 (10 µM) served as a positive inhibitor control in the 
allopurinol experiment and completely inhibited BCRP-
mediated rosuvastatin transport.
ATP-dependent transport was calculated as the differ-
ence between rosuvastatin uptake in the presence and 
absence of ATP. Relative transport values were then cal-
culated by comparing the ATP-dependent rosuvastatin 
uptake in the presence of febuxostat or allopurinol with 
that in the presence of vehicle. To determine the half-max-
imal inhibitory concentration of febuxostat and allopurinol, 
the relative transport values were fitted to the four-param-
eter logistic regression model as shown in Eq. 1, using 
GraphPad Prism version 8 (GraphPad Software, San 
Diego, CA):
where minimum and maximum correspond to the pla-
teaus of minimum and maximum relative transport (%), [I] 
is the concentration of inhibitor, and h is the Hill slope. In 
the case of febuxostat, the minimum value was constraint 
to 0.
RESULTS
Effect of febuxostat on rosuvastatin pharmacokinetics
Febuxostat increased the Cmax of rosuvastatin on average 
2.1-fold (90% CI 1.8–2.6; P = 5 × 10−5) and the AUC0–∞ of 
rosuvastatin 1.9-fold (90% CI 1.5–2.5; P = 0.001; Figure 2, 
Table 2). In addition, the amount of rosuvastatin excreted 
into urine was increased 1.8-fold (90% CI 1.2–2.7; P = 0.03) 
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Marked interindividual variability was observed in the in-
teraction between febuxostat and rosuvastatin (Figure 3). 
The effect of febuxostat on rosuvastatin AUC0–∞ ranged 
among the individual participants from no increase to 5.3-
fold increase. Three of the participants were homozygous 
and one was heterozygous for the SLCO1B1 c.521T>C re-
duced function variant. One participant was homozygous 
and two heterozygous for the ABCG2 c.421C>A variant. The 
SLCO1B1 or ABCG2 genotypes did not seem to be related 
to the extent of interaction (Figure 3).
Effect of allopurinol on rosuvastatin pharmacokinetics
In contrast to febuxostat, allopurinol had no statistically 
significant effect on the pharmacokinetics of rosuvastatin 
(Figure 2; Table 2). However, there was a tendency for a 
prolonged t½ of rosuvastatin during allopurinol treatment 
(10.9 hours vs. 6.4 hours during placebo), but the effect was 
not statistically significant (P = 0.08). In two of three indi-
viduals with the SLCO1B1 c.521C/C genotype, allopurinol 
seemed to increase the AUC0–∞ of rosuvastatin to the same 
extent as febuxostat (Figure 3).
Effects of febuxostat and allopurinol on BCRP-
mediated rosuvastatin transport in vitro
In membrane vesicles prepared from BCRP-overexpressing 
human embryonic kidney (HEK293) cells, febuxostat in-
hibited the ATP-dependent uptake of rosuvastatin with an 
half-maximal inhibitory concentration of 0.35 µM (Figure 4). 
Allopurinol did not inhibit rosuvastatin uptake with concen-
trations up to 200 µM.
Febuxostat and allopurinol pharmacokinetics
The plasma concentrations of febuxostat and allopurinol 
varied moderately between individual participants (Table 3). 
The Cmax and AUC0–24 of febuxostat varied 5.0-fold and 
3.0-fold and those of allopurinol 1.8-fold and 4.7-fold.
DISCUSSION
Previous in vitro data have suggested that febuxostat in-
hibits BCRP at clinically relevant concentrations.8 By 
contrast, allopurinol and its metabolite oxypurinol have not 
inhibited BCRP in vitro.13 To study the effects of the two 
Figure 2 The effect of allopurinol and febuxostat on the plasma concentrations of rosuvastatin. Ten healthy volunteers ingested as 
pretreatment either 300 mg allopurinol on days 1–7 (a), or 120 mg febuxostat on days 4–7 (b), or placebo. Rosuvastatin 10 mg was 
administered 1 hour after the administration of pretreatment on day 6 of each of the three phases. Data are geometric means with 90% 
confidence interval. For clarity, some error bars have been omitted. Insets depict the same data on a semilogarithmic scale.


















































Allopurinol phase to 
placebo phase ratio  
(90% CI); P value Febuxostat phase
Febuxostat phase to placebo phase ratio 
(90% CI); P value
Rosuvastatin
Cmax, ng/mL 5.0 (75%) 6.1 (100%) 1.22 (1.02–1.47); P = 0.08 10.7 (62%) 2.13 (1.76–2.58); P = 5 × 10
−5
Tmax, hour 4.5 (0.5–6.0) 5.0 (1.5–8.0) P = 0.15 3.5 (1.0–5.0) P = 0.15
t½, hour 6.4 (63%) 10.9 (62%) 1.72 (1.03–2.85); P = 0.08 6.3 (29%) 1.00 (0.75–1.33); P = 0.99
AUC0–∞, ng·hour/
mL
42.6 (76%) 53.5 (77%) 1.26 (0.98–1.61); P = 0.13 82.5 (44%) 1.93 (1.51–2.48); P = 0.001
Ae, mg 0.45 (78%) 0.45 (101%) 0.99 (0.69–1.43); P = 0.98 0.79 (55%) 1.76 (1.16–2.66); P = 0.03
Clrenal, mL/minute 261 (43%) 225 (36%) 0.86 (0.65–1.14); P = 0.36 213 (36%) 0.82 (0.58–1.14); P = 0.30
The pretreatments in the three phases were as follows: placebo (days 1–7), allopurinol 300 mg once daily (days 1–7), and febuxostat (placebo on days 1–3 
and 120 mg febuxostat on days 4–7). Data are given as geometric mean with geometric coefficient of variation, except for Tmax, which is given as median with 
range. The geometric mean ratios between the phases are given with 90% CIs. 
Ae, amount excreted into urine; AUC, area under the plasma concentration-time curve from zero to infinity; Clrenal, renal clearance; Cmax, peak plasma con-
centration; t½, elimination half-life; Tmax, time to Cmax.
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urate-lowering drugs on BCRP activity in humans, we in-
vestigated their effects on the pharmacokinetics of the 
BCRP-substrate rosuvastatin in healthy volunteers. Our 
results indicate a difference in the interaction potentials of 
the two xanthine oxidase inhibitors. In this study, febuxostat 
markedly increased the plasma concentrations of rosuvas-
tatin. After the administration of febuxostat, the Cmax of 
rosuvastatin was more than doubled and the AUC0–∞ almost 
doubled when compared with those measured after the ad-
ministration of placebo. The Clrenal of rosuvastatin, however, 
was not altered by administration of febuxostat. In contrast 
to febuxostat, allopurinol had no significant effect on the 
pharmacokinetic variables of rosuvastatin. The t½ of rosu-
vastatin, however, tended to be prolonged by allopurinol. In 
vitro, febuxostat, but not allopurinol, strongly inhibited the 
BCRP-mediated transport of rosuvastatin, consistent with 
the observations from previous in vitro studies using urate 
or pitavastatin as a substrate.8,13
The findings that febuxostat raised the Cmax and AUC0–∞ 
of rosuvastatin with no effect on its t½ or renal clearance 
suggest that febuxostat increased the oral bioavailability 
of rosuvastatin. Given that febuxostat is a potent inhibitor 
of BCRP in vitro, the most likely mechanism underlying 
the interaction is inhibition of the BCRP-mediated efflux 
of rosuvastatin in the small intestinal wall. If the trans-
porter inhibition is restricted to the small intestinal wall, 
it should not affect the t½ of rosuvastatin. The intesti-
nal concentrations of febuxostat are likely much higher 
than its systemic concentrations, which may result in a 
strong inhibition of the BCRP in the gut, but not neces-
sarily in other tissues. Of note is that homozygosity for 
the ABCG2 c.421C>A SNV has a remarkably similar im-
pact on rosuvastatin pharmacokinetics, having no effect 
on its t½.
11 However, rosuvastatin is also a substrate of the 
organic anion transporting polypeptide (OATP) 1B1, 1B3, 
and 2B1 influx transporters expressed on the basolateral 
membrane of human hepatocytes.14–17 As yet, there are 
no data on febuxostat’s potential to inhibit OATPs. In vivo 
in humans, homozygosity for the reduced function vari-
ant c.521T>C in the SLCO1B1 gene encoding OATP1B1 
has raised rosuvastatin Cmax about 1.8–2.7-fold and AUC 
Figure 3 The individual rosuvastatin area under the plasma 
concentration-time curve from zero to infinity (AUC0–∞) values in 
healthy volunteers after the administration of 10 mg rosuvastatin 













































Figure 4 The effect of febuxostat and allopurinol on the BCRP-
mediated transport of rosuvastatin in the vesicular transport 
assay. BCRP-expressing membrane vesicles were incubated in 
the presence of rosuvastatin and febuxostat (a) or allopurinol (b). 
The ATP-dependent transport of rosuvastatin in the absence of 
test compounds was set as 100%. Data are means ± SD (n = 6).
Table 3 Pharmacokinetic variables of allopurinol and febuxostat 
on day 6 of 300 mg allopurinol once daily, or on day 3 of 120 mg 
febuxostat once daily in 10 healthy volunteers
Variable Geometric mean (geometric CV)
Allopurinol
Cmax, µg/mL 2.0 (21%)
t½, hour 1.3 (50%)
AUC0–24, µg·hour/mL 5.7 (46%)
Febuxostat
Cmax, µg/mL 4.3 (49%)
t½, hour 6.0 (21%)
AUC0–24, µg·hour/mL 12.3 (39%)
AUC, area under the plasma concentration-time curve from zero to 
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about 1.7–2.2-fold.18–20 In addition, a single intravenous 
dose of rifampin (INN, rifampicin), a strong inhibitor of 
OATP1B1 and OATP1B3, has raised the Cmax and AUC of 
rosuvastatin about 8-fold to 9-fold and 3-fold to 3.5-fold, 
respectively.21 However, unlike the ABCG2 c.421C>A vari-
ant or febuxostat, both the SLCO1B1 c.521T>C variant 
and rifampin tended to shorten the t½ of rosuvastatin. The 
shortened t½ could indicate a reduced volume of distribu-
tion due to impaired hepatic uptake. Taken together, these 
findings indicate that the febuxostat-rosuvastatin interac-
tion is indeed most likely caused by inhibition of the BCRP 
in the small intestine.
Three individuals recruited for the study were homozygous 
for the SLCO1B1 c.521T>C variant and one for the ABCG2 
c.421C>A variant. These variants did not seem to be related 
to the extent of interaction between febuxostat and rosu-
vastatin, but due to the limited sample size, no conclusions 
can be drawn. Interestingly, the AUC0–24 of febuxostat was 
increased 1.8-fold in individuals homozygous for SLCO1B1 
c.521T>C as compared with the noncarriers and one het-
erozygote (data not shown), suggesting that OATP1B1 is 
important for the hepatic uptake of febuxostat. Further stud-
ies are required to verify this preliminary finding.
The finding that febuxostat inhibits BCRP in vivo in hu-
mans may make it a useful index inhibitor for drug-drug 
interaction studies in humans. Moreover, it can be safely 
administered to healthy volunteers and its pharmacoki-
netic steady-state is reached rapidly, which are desirable 
characteristics of index inhibitors.22 In vitro, febuxostat is a 
weak inhibitor of CYP2C8 and CYP2D6, but it does not in-
hibit CYP1A2, CYP2C9, CYP2C19, or CYP3A4.23,24 In vivo 
in humans, febuxostat had no effect on the pharmacoki-
netics of the CYP2C8 probe substrate rosiglitazone and 
only slightly increased the AUC of the sensitive CYP2D6 
substrate desipramine (by 12%).24,25 These data indicate 
relative selectivity for BCRP compared with the CYP en-
zymes. However, more studies are needed to determine 
whether febuxostat inhibits OATPs or other drug trans-
porters. Moreover, as febuxostat is a strong inhibitor of 
xanthine oxidase, it can interact with drugs metabolized 
by this enzyme, such as the thiopurines.
Cyclosporine and eltrombopag are among the best doc-
umented examples of clinical BCRP inhibitors, but both of 
them are nonselective.22 Cyclosporine has raised the AUC 
of rosuvastatin 7.1-fold.26 However, cyclosporine is also 
a potent inhibitor of OATP1B1, OATP1B3, and OATP2B1, 
which likely explains the extent of the cyclosporine-rosuvas-
tatin interaction.16,27 In addition, cyclosporine inhibits, for 
example, the P-glycoprotein and CYP3A4.28,29 On the other 
hand, eltrombopag has raised rosuvastatin AUC only 1.6-
fold. Eltrombopag also inhibits OATP1B1, OATP1B3, and 
OATP2B1 in vitro.30–32
Patients on urate-lowering pharmacotherapy are at high 
risk for comorbidities and polypharmacotherapy. Gout is 
strongly associated with metabolic syndrome and cardio-
vascular diseases.4,33 Given that febuxostat presumably 
increased the intestinal absorption of rosuvastatin, the 
concomitant use of febuxostat may enhance the cho-
lesterol-lowering efficacy of rosuvastatin and the risk of 
rosuvastatin-induced muscle toxicity.34–36 In addition to 
rosuvastatin, several other statins are BCRP substrates.37 
In previous pharmacokinetic studies in humans, the AUCs 
of atorvastatin and fluvastatin were increased 1.7-fold in 
individuals homozygous for the ABCG2 c.421C>A variant, 
as compared with noncarriers.11,38 Thus, febuxostat may 
increase the exposure to atorvastatin and fluvastatin. On 
the other hand, the ABCG2 c.421C>A variant has had no 
significant effect on the AUC of simvastatin acid, pitavasta-
tin, or pravastatin.38–40 However, in patients with established 
cardiovascular disease, febuxostat increases all-cause 
and cardiovascular mortality compared with allopurinol.41 
Febuxostat use is, therefore, restricted to exceptional cases 
only and its concomitant use with statins is unlikely.
The present study was carried out with a single low dose 
of rosuvastatin in healthy volunteers. Because rosuvastatin 
shows linear pharmacokinetics and its pharmacokinetics do 
not change after multiple dosing, the present results can be 
extrapolated to higher doses and continuous treatment.36 
Marked interindividual variability existed in the interaction 
between febuxostat and rosuvastatin within the homog-
enous group of healthy volunteers of the present study. 
Patients using febuxostat often have comorbid diseases 
and may use other drugs as well, which may further increase 
interindividual variability in the extent of its interactions with 
BCRP substrates.
To conclude, febuxostat but not allopurinol markedly 
increases the plasma concentrations of rosuvastatin in 
healthy volunteers. It is plausible that the mechanism un-
derlying the febuxostat-rosuvastatin interaction is inhibition 
of the BCRP-mediated efflux of rosuvastatin in the gut wall. 
Potential BCRP-mediated interactions should be taken into 
consideration when planning urate-lowering therapy for pa-
tients with multiple medications. Furthermore, febuxostat 
could be a useful BCRP index inhibitor in drug-drug inter-
action studies.
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